Natdac

Natdac (Daclatasvir Dihydrochloride) is a treatment for chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection. It is always prescribed with sofosbuvir, and depending on the genotype and underlying medical conditions, with or without ribavirin.

Most people will be prescribed one 60mg tablet daily. Natdac is an oral tablet. It should be swallowed whole with a glass of water. It can be taken with or without food.

Treatment with Natdac (Daclatasvir Dihydrochloride) will usually last for a period of 12 weeks.

Natdac should always be taken concurrently with Sofosbuvir. In some cases it should be taken with Ribavarin also. Ribavirin will also be prescribed in post-transplant patients, in patients with decompensated cirrhosis, or in patients with Genotype 3 infection and compensated cirrhosis.

Natdac (Daclatasvir Dihydrochloride) and Sofosbuvir treatment can result in some unwanted side effects. Most of these are mild to moderate. The most commonly reported side effects are headache, fatigue, nausea and diarrhea.

When Ribavirin is also being taken there are some additional possible side effects such as anemia, rash, insomnia, dizziness and somnolence.

Natdac (Daclatasvir Dihydrochloride) and Sofosbuvir when taken with Amiodarone can result in serious symptomatic bradycardia. This risk is higher in patients who are also taking beta-blockers or patients with heart problems or liver disease.

Tell your doctor if you are taking any of the following before beginning treatment: phenytoin, carbamazepine, rifampin, and St. John’s wort.

The following medicines are known to interact with Daclatasvir:

• Protease inhibitors (atazanavir with ritonavir, indinavir, nelfinavir, saquinavir)
• Other antiretrovirals (eg. atazanavir/cobicistat, elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)
• Non-nucleoside reverse transcriptase inhibitors (efavirenzb, etravirine, nevirapine)
• Strong CYP3A inhibitors (eg. clarithromycin, itraconazole, ketoconazole, nefazodone, posaconazole, telithromycin, voriconazole)
• Moderate CYP3A inducers (eg. bosentan, dexamethasone, modafinil, nafcillin, rifapentine)
• Anticoagulants (dabigatran etexilate mesylate)
• Cardiovascular agents (Amiodarone, Digoxin)
• HMG-CoA reductase inhibitors (Atorvastatin, Fluvastatin, Pitavastatin, Pravastatin, Rosuvastatin, Simvastatin)
• Narcotic Analgesics (buprenorphine, buprenorphine/naloxone)

Daclatasvir may increase the risk of birth defects and miscarriage. Men whose partners are pregnant, pregnant women, women who are trying to become pregnant, and men whose partners are trying to become pregnant shoulde exercise care and check with their doctor before using Natdac (Daclatasvir Dihydrochloride).

Daclatasvir may not be safe to use in patients under 18 years old.